Abstract: Psychiatric genomics is a rapidly growing field that holds much promise for improving risk prediction, prevention, diagnosis, treatment selection, and understanding of the pathogenesis of patients' symptoms. The field of psychiatry (i.e., professional organizations, mental health clinicians, educational institutions), however, needs to address numerous challenges to promote the responsible translation of genomic technologies and knowledge into psychiatric practice. The goal of this article is to review how clinicians currently encounter and use genomics in the clinic, to summarize the existing literature on how clinicians feel about the use of genomics in psychiatry, and to analyze foreseeable ethical and legal challenges for the responsible integration of genomics into psychiatric care at the structural and clinic levels. Structural challenges are defined as aspects of the larger system of psychiatric practice that constitute potential barriers to the responsible integration of genomics for the purposes of psychiatric care and prevention. These structural challenges exist at a level where professional groups can intervene to set standards and regulate the practice of psychiatry and genomics. Clinic-level challenges are day-to-day issues clinicians face when managing genomic tests in the clinic. We discuss the need for action to mitigate these challenges and maximize the clinical and social utility of psychiatric genomics, including the following: expanding genomics training among mental health clinicians; establishing practice guidelines that consider potential clinical, psychological, and social implications of psychiatric genomics; promoting an integrated care model for managing genomics in psychiatry; emphasizing patient engagement and informed consent when managing genomic testing in psychiatric care.
P sychiatric genomics is a rapidly growing field that holds much promise for improving risk prediction, prevention, diagnosis, treatment selection, and understanding of the pathogenesis of patients' symptoms. [1] [2] [3] [4] [5] [6] In this article we examine the foreseeable ethical, legal, and practical challenges that the field of psychiatry (i.e., professional organizations, mental health clinicians, educational institutions) need to address in translating the knowledge and technologies of psychiatric genomics into clinical practice.
Many psychiatric conditions are highly heritable, with the highest rates seen in schizophrenia (.81), autism spectrum disorder (.80), and bipolar disorder (.75). 1 Nevertheless, for years, researchers studying the genetic foundations of mental health disorders struggled to obtain reliable findings. 4, [6] [7] [8] Recently, the emergence of multinational research consortia, such as the Psychiatric Genomics Consortium, 9 has powered successful large-scale, genome-wide association studies (GWAS) for psychiatric disorders. 2, 10 Despite these early successes, the clinical utility of the single-nucleotide polymorphism (SNP) arrays used for GWAS is limited. Although more than 140 genomic loci reliably associated with schizophrenia have already been identified in GWAS, these genomic loci contribute only a small amount to the overall risk of developing schizophrenia. 11, 12 Furthermore, only a few copy-number variants, such as 22q11.2 (attention-deficit/hyperactivity disorder, autism spectrum disorder, schizophrenia) and 17p11.2 (autism spectrum disorder), have been linked to psychiatric disorders, 13, 14 and the prevalence of copy-number variants among patients with psychiatric disorders is relatively low. 5, 14 Moreover, the most recent estimated heritability based on SNPs identified in GWAS is modest (45% for schizophrenia, 37% for obsessive-compulsive disorder, 21% for bipolar disorder, and about 8% for major depressive disorder and substance use disorders). 2 Finally, while GWAS have identified genomic markers that may predict response to antidepressant, antipsychotic, lithium, and stimulant therapies (e.g., 4p15.1, 9q33.3), identify individuals at risk for antipsychotic-induced weight gain (e.g., MC4R), and predict the risk of severe cutaneous side effects in patients taking carbamazepine (e.g., HLA-A*3101), most studies have been limited by their relatively small sample sizes. 15, 16 Given the limitations of GWAS, collecting information on family history remains, at present, the most reliable way of predicting disease risk and treatment response.
Despite these limitations, the success of large-scale GWAS and the decreasing cost of array-based and sequencingbased genomic tests (whole genome and whole exome sequencing) have revitalized psychiatric genomics and led to a redoubling of efforts, using large samples of cases and controls, to examine the genomic architecture of other psychiatric disorders. 2, 17 An examination of the critical ethical, legal, and practice challenges that psychiatrists will face as psychiatric genomics research is translated into clinical care can help identify and generate potential solutions that maximize the research's clinical and social utility.
Researchers and private enterprises are actively attempting to translate emerging knowledge about psychiatric genomics into clinically useful information to improve mental illness care and prevention. 5, [18] [19] [20] In addition, clinicians are already encountering genomic findings in their practices-for example, when patients bring in their personal results from participating in a research study or, more commonly, from direct-to-consumer genetic testing. Within the next decade or two, genomic data will likely be ubiquitous in psychiatric practice. To integrate genomics in a way that promotes the best interests of stakeholders such as at-risk individuals, patients, patients' relatives, and mental health clinicians, the field of psychiatry must address critical structural and clinic-level challenges.
Structural challenges are defined here as aspects of the larger system of psychiatric practice that constitute potential barriers to the responsible integration of genomics for the purposes of psychiatric care and prevention. These structural challenges exist at a level where they can be more effectively intervened upon by professional groups that set standards and regulate the practice of psychiatry and genomics (e.g., American Psychiatric Association, International Society of Psychiatric Genetics [ISPG] , psychiatry residency programs, continuing education programs) than by individual mental health clinicians. Clinic-level challenges are defined as dayto-day issues that clinicians will face when managing genomic tests and responding to specific types of findings in the clinical setting.
The goals of this article are to review how clinicians currently encounter and use genomics in the clinic, to summarize existing literature on how clinicians feel about the use of genomics in psychiatry, analyze foreseeable ethical, legal, and practical challenges for the responsible integration of genomics into psychiatric care at the structural and clinic levels, and provide recommendations about how these challenges may be addressed.
GENOMICS IN PSYCHIATRIC CLINICS TODAY
Many psychiatrists already encounter genomic technologies in their practice, and soon this will be the reality for most. As genomic knowledge and clinical applications develop, psychiatrists themselves may eventually order genomic tests on a regular basis and use these results to aid in risk prediction, diagnosis, prognosis, and treatment selection for mental disorders (Table 1) . In a 2014 study (n = 372), 14% of psychiatrists reported having ordered a genetic test in the past six months, and 36% started conversations about genetic testing with their patients over the same period. 21 These psychiatrists were recruited via email from the American Medical Association master list, and 57% worked primarily in private practice. According to a separate study based on the same sample, the most commonly ordered tests by psychiatrists were pharmacogenomic tests (47% of genetic tests ordered), such as those analyzing cytochrome p450 genes, and the remainder were diagnostic or predictive tests for various conditions, including Alzheimer's disease (10%), Fragile X syndrome (6%), Down syndrome (4%), and Huntington's disease (4%). 22 Although the vast majority of tests ordered by psychiatrists are for neuropsychiatric conditions, a minority (10%) reported ordering tests for other medical conditions, such as breast cancer, 22 and 18% discussed prenatal genetic testing for nonpsychiatric conditions with their patients. 21 As patients and the general public become increasingly aware of the use of genomics in clinical practice, 23 psychiatrists will be under mounting pressure to order testing or to incorporate genetic findings into their practices. Already, 42% of psychiatrists report having had a patient ask them about genomic testing over the previous six months, 21 and 29% report having received commercial advertising from genetictesting laboratories. 22 Psychiatrists also encounter genomic test results when their patients get direct-to-consumer genomic testing and bring the results to the clinic in hopes their clinicians might help interpret the findings or potentially use the findings to inform their clinical management. In a recent study, nearly 15% of psychiatrists reported having been asked about direct-to-consumer genomic testing by patients. 22 Psychiatrists may confront a similar situation when their patients participate in research that involves genomic testing in which researchers return clinically relevant findings to participants-a rising practice in genomics research 24 with participants then bringing those findings to the clinic. [25] [26] [27] [28] [29] Other patients may request the use of emerging psychiatric pharmacogenetic tests in an effort to find more effective medication for managing their symptoms or to reduce the risk for severe side effects. guiding treatment. 30 One study (n = 352) recruited psychiatrists attending a continuing education course on psychopharmacology; 21% of the psychiatrists reported that their primary work activity was hospital or inpatient psychiatry, and 52% reported that it was outpatient psychopharmacology. 30 In this sample the large majority (83%) of psychiatrists reported that they felt it to be their role to discuss and advise patients about the relation of genetic information to mental health disorders, and 87% routinely obtained family histories of psychiatric illness. These studies indicate a recognition among clinicians of the potential value of psychiatric genomics and a willingness to integrate it into their practice.
Despite their enthusiasm about the promise of genetics in psychiatry, many clinicians report a lack of confidence about how to apply genomics in clinical practice. 30 Psychiatrists also disagree on who should be tested. When asked about a hypothetical genetic test to detect risk for schizophrenia, over 73% of 64 surveyed clinical psychiatrists (members of the New York State Psychiatric Society; the study also included researchers in psychiatric genetics) favored administering it to patients with chronic schizophrenia and first-episode psychosis. 31 Fewer psychiatrists supported using this test with other populations: 48% stated that they would test the rest of the family if one person tested positive; 41% would test adolescents and young adults with social problems; and others would test all psychiatric patients (22%) and all newborns (20%). 31 Approximately a quarter of psychiatrists felt that no one should be tested. There was likewise no clear consensus among them on how genomic findings should be used. Notably, however, on the particular question of whether they would prescribe "preventive medication" for someone who tested positive on the hypothetical genomic test for schizophrenia risk, 100% of the clinicians in the study favored such an approach, whereas only 52% of the surveyed researchers-a group that included MDs, MD/PhDs, PhDs, and holders of other college degrees-agreed with that approach. 31 
Ethical Reservations about Genomics in Psychiatry
Mental health clinicians also express ethical concerns about integrating psychiatric genomics into practice. Almost half of psychiatrists and neurologists surveyed in one study reported concern that patients would be subject to psychological harm as a result of undergoing genetic testing. 22 Another study reported that psychiatrists believe genomic results could carry decreased "expectations for children who carry highrisk genes" (63%) and "increased stigmatization" (35%). 30 In the same study, clinicians also expressed concern that increased knowledge about psychiatric genetics may lead to denial of insurance (91%) and employment discrimination (78%). In addition, psychiatrists face medicolegal and ethical issues when managing genetic findings. A small but significant number of psychiatrists report having encountered privacy concerns when discussing genetic findings with patients. According to one survey, 8% of psychiatrists have had patients ask them not to document genetic findings in their medical records, 22 and in this sample, 5% of psychiatrists reported having actually excluded genetic information from the medical records. 21 Psychiatrists must strike a difficult balance between maintaining the trust necessary for an effective clinician-patient relationship (therapeutic alliance) and addressing concerns about potential legal liability for not including medical findings in patients' records. One might suppose that the above privacy concerns would have been allayed by the Genetic Information Nondiscrimination Act (GINA) of 2008, which protects against genomic-based discrimination in health insurance and employment. However, given that the last two studies 21, 22 were published six years after GINA was passed, it is reasonable to infer that concerns about potential misuses of genomic information persist. 34 Furthermore, clinicians may be unaware of GINA regulations or how to manage, in practice, genomic information consistent with GINA, 35 as we discuss in more detail below. Patient and clinician concerns about the privacy of genomic information may be explained, in part, by lack of public visibility of genomic antidiscrimination laws 36 or by the particular scope of GINA's protections, which bars genomics-based discrimination only in the context of health insurance and employment. Thus, existing antidiscrimination regulations may not protect against other concerns that clinicians may have, such as the use or misuse of genomic results in other areas (e.g., education, life and disability insurance, and mortgage or other lending scenarios). 37, 38 In fact, 47% of 394 psychiatrists and neurologists somewhat or strongly disagreed with the statement "Legal protections against genetic discrimination are adequate." 22 These findings suggest the need for further guidelines, legal protections, and educational campaigns regarding the implications of genomic findings in order to minimize genomics-based mental health stigma and other unintended consequences of genomic testing in psychiatric care and prevention.
STRUCTURAL CHALLENGES
The field of psychiatry must address a series of key structural challenges in order to promote the responsible integration of genomics into psychiatric care and illness prevention. These challenges, described in turn below, affect the field of psychiatry as a whole and will likely require collaborative solutions across organizations that help set standards for psychiatric practice and education.
Lack of Training in Genomics
Psychiatrists across multiple studies report that they do not feel they have the expertise necessary to manage genomic testing and findings. In a sample of 45 psychiatrists recruited using the American Medical Association master file (58% reported that their primary practice was outpatient psychopharmacology; 13% reported that it was hospital or inpatient psychiatry; and 29% had multiple responses), over 90% reported not feeling competent or prepared "to offer genetic tests and interpret the results." 32 The authors replicated this result in a subsequent sample of 135 psychiatry residents and 100 educators, 39 noting a lack of training in psychiatric genomics. A total of 39% of educators and 55% of trainees from this study reported that their respective residency programs placed "little or no emphasis" on psychiatric genetics. Moreover, when educators were asked to rate their programs' readiness to provide training in this area, nearly half (46%) responded that "few or no" faculty at their respective institutions had expertise in genetics or genomics. Other studies similarly reflect gaps in genomic knowledge among clinicians. One study found that fewer than 1% of 352 psychiatrists surveyed answered all nine multiple-choice questions about genetics correctly and that the median number of correct answers was four. 30 In a more recent study, most psychiatrists overestimated or underestimated the contribution of genetics to various disorders, including depression and anorexia. 21 One study 32 found that 87% of psychiatrists were not aware of medical geneticists or genetic counselors in the geographic areas where they practiced, and most did not know whether genetic testing or counseling was covered by the majority of insurance plans in their geographic areas.
Absence of Professional Guidelines and Legal Standard of Care
As shown in Table 1 , genomic testing has a number of potential uses in psychiatry; available evidence suggests, however, that psychiatrists disagree as to when and with which populations it would be appropriate to use genetic tests. 31 A critical structural challenge faced by psychiatrists is the lack of a clear standard of care and professional guidelines for using genomic tests and managing the findings. Currently, the only guidelines focused on the use of genomics in psychiatric care are the ones offered by the International Society of Psychiatric Genetics. The ISPG's Genetic Testing Statement offers general recommendations on using genetic tests to assist in diagnosing and identifying high-risk individuals, and to guide treatment. It also briefly addresses the report of incidental or secondary-target findings and some of the psychological, ethical, and clinical implications of genetic testing. The statement advocates for additional research initiatives, educational programs, and privacy safeguards, but does not discuss in detail the management of specific psychiatric genomic findings. 40 The document is a short one, however, that is limited in scope and was not meant to provide the in-depth guidance that the field currently needs. It is possible that future revisions will expand the current guidelines to address these issues in more detail.
The American College of Medical Genetics and Genomics (ACMG) has recommended that 59 secondary-target, medically actionable genes be examined when clinical genomic sequencing is conducted, and has offered guidelines about the management of genomic information with pediatric patientswhom the ACMG discourages testing for late-onset conditions unless it is in the child's best medical and overall interest. [41] [42] [43] [44] [45] [46] [47] [48] In theory, the ACMG recommendations apply to psychiatric practice, though they do not address the particularities of the field. As such, psychiatrists and courts attempting to incorporate genomics or to judge the adequate use of genomics in the clinic are currently navigating mostly unchartered terrain.
Certain aspects of psychiatry generate unique challenges. Psychiatric genomics has progressed immensely in recent years, but it is at a relatively early stage compared to other fields of genomics. Psychiatric disorders are also highly polygenic and multifactorial, which complicates the interpretation and management of findings, and distinguishes them from the mostly Mendelian disorders addressed in the ACMG recommendations. Little research has been conducted regarding the psychological and social impact of genomic information on patients or individuals at risk for psychiatric disorders. Further, the high degree of mental health stigma increases the risk for discrimination based on psychiatric genomic findings. As guidelines are developed and adopted in practice, they will help establish a much needed standard of care to guide clinicians, 49 especially if the the guidelines address the particularities of psychiatric practice. It would be useful for professional organizations such as the American Psychiatric Association or others to establish committees or collaborate with the ISPG, to periodically evaluate the state of psychiatric genomics, and to release recommendations that can help inform and guide clinicians and patients about the responsible use of genomic testing in psychiatry.
Lack of Evidence of Clinical Utility Before Implementation
Genomic tests are already making inroads into psychiatric practice, despite substantive questions about their clinical utility. For example, pharmacogenetic tests could potentially help clinicians minimize trial and error by selecting medications and dosages that are more likely to be effective and less likely to cause severe side effects. Evidence suggests a substantial willingness to use these tests. One study shows that psychiatrists are more likely to order pharmacogenetic tests (47%) than any other type of genetic test, versus the 2% of neurologists likely to do so. 22 Despite this willingness, plus select findings that the use of pharmacogenomic testing may improve clinical outcomes, 18, 20 critics contend that the available evidence is simply not strong enough at present to support the use of such testing. 50 A similar example comes from the U.S. Department of Veterans Affairs, which awarded a contract to Assurex Health to make their pharmacogenomics GeneSight® Psychotropic test available for use in VA facilities nationwide. 51 A couple of years after the contract was awarded, the VA issued a report concluding that current evidence failed to demonstrate that the GeneSight® Psychotropic test is more effective than usual care in reducing remission of depression symptoms. 52 While some psychiatrists and institutions may be enthusiastic about pharmacogenetics, surveys reveal skepticism among many psychiatrists, with some asserting that pharmacogenomic testing is being "overhyped" and "overused."
53 At best, clinicians using these tests may be misspending both limited health care resources and patients' money, given that these tests are generally not covered by insurance; the companies consider the tests to be investigational and to lack sufficient evidence of clinical utility. [54] [55] [56] [57] At worst, psychiatrists using pharmacogenetic tests are potentially putting patients at risk by making clinical-management determinations with no solid evidence for clinical utility.
Debates continue over whether and how pharmacogenetic testing should be regulated to avoid these risks. 58, 59 The U.S. Food and Drug Administration has proposed a regulatory framework for these tests 60 but has not issued final guidance. Moreover, this framework may not apply to previously marketed tests that become "grandfathered."
61 Professional organizations and government institutions can help raise awareness and provide guidance by circulating information about emerging pharmacogenetic tests and their clinical utility. These actions would bring relevant and curated information to a wider audience of clinicians and patients, while also relieving clinicians of the full burden of evaluation. Relying solely on clinician discretion is especially problematic because the above studies indicate that clinicians lack the knowledge and confidence required to manage these tests in practice. Federal health care agencies such as the Centers for Medicare and Medicaid Services could also promote evidence-based genomic medicine by requiring data of clinical utility in order to obtain coverage.
62,63
CLINIC-LEVEL CHALLENGES Mental health clinicians constantly have to manage novel technologies (e.g., drugs) or novel applications of biomedical technologies. Some could argue that genomic testing is just one more biomedical technology, but it's not. Because of the amount of genomic information potentially that may be generated by these tests, coupled with the complexity of the information and the impact it could have on various aspects of clinical practice (see Table 1 ), we need to carefully examine and address the kinds of day-to-day challenges that genomic testing will raise. These challenges, detailed below, include ethical, legal, and practice issues related to the management of genomic findings-issues that may help inform risk prediction, diagnosis, prognosis, and treatment for psychiatric illness, along with the management of health risks unrelated to mental health.
Risk Prediction for Asymptomatic Individuals
If genomic variants could help to reliably identify individuals at risk for a disorder, limited health care resources could be better allocated to provide services to these individuals. In addition, reliably identifying individuals at risk could help improve clinical outcomes by monitoring symptoms and intervening as soon as an individual meets criteria for a psychiatric disorder. In the case of psychotic disorders, research suggests that shorter duration of untreated psychosis is associated with improved clinical outcomes. 64, 65 Shorter duration of untreated symptoms is likewise associated with improved outcomes for depression. 66 The ability to identify a group of individuals who are at risk for psychiatric disorders could also help researchers study and develop clinically useful interventions for these at-risk populations, which may delay or prevent the onset of psychiatric disorders. [67] [68] [69] It is likely that most genomic tests in clinical psychiatry will be performed in patients with active psychiatric symptoms. However, clinicians may offer (or individuals may request) genomic tests for asymptomatic people-for example, someone with a family history of psychiatric disorders who wants to know if she is at an increased genomic risk. If tests in these individuals reveal an increased risk for a disorder, psychiatrists will likely be called upon to determine whether the individuals are candidates for early interventions and whether, when, and which early interventions should be offered. In an attempt to prevent or delay the onset of illness, psychiatrists might feel compelled to offer clinical interventions to individuals testing positive, much in the way some psychiatrists currently offer preventive psychotherapy and even pharmacotherapy to individuals that meet ultra-high risk criteria for psychosis. [70] [71] [72] If psychiatrists do not comply with patient requests to provide "preventive" pharmacotherapy, patients could potentially "shop around" for a clinician willing to prescribe these medications.
Offering "preventive" pharmacotherapy regarding genomic risks is ethically problematic, however, for a number of reasons. The penetrance of currently known genomic variants associated with psychiatric disorders is generally low. As such, while asymptomatic individuals testing positive for genetic variants associated with psychiatric disorders may be at an increased risk compared to the general population, it is still unlikely that they will ever meet criteria for a disorder. Further, little research suggests that medications help prevent psychiatric disorders in asymptomatic individuals or even in those with subthreshold symptoms, and the risks of offering such interventions could outweigh the projected benefits, especially if a drug carries substantial risk for adverse effects, as in the case of antipsychotics. 72 Even in cases where risk prediction could confer potential clinical benefits, it presents certain ethical and clinical problems for psychiatrists, including the potentially negative emotional responses of asymptomatic individuals who learn about their risks for psychiatric disorders. When testing asymptomatic populations, psychiatrists should be prepared to provide support to individuals receiving results, whether it is in the form of office-based supportive therapy or referrals to specialists, such as genetic counselors. Most psychiatrists, however, do not routinely refer patients to genetic counselors and are not even aware of how and where to direct referrals. 32 Consequently, in order to act in the best interest of their patients, psychiatrists who order such tests should make an effort to educate themselves about the availability of counseling services.
Identifying asymptomatic individuals at risk for psychiatric disorders also raises concerns about the use of this information outside the medical realm. For example, as noted above, in the United States, GINA 34 protects against genomic-based discrimination in health insurance and employment but does not provide protection in any other aspects of life such as disability and life insurance, or even mortgages and student loans. 37, 38 Given the potential for discrimination, psychiatrists should try to safeguard genetic information by ensuring compliance with HIPAA, securing electronic medical records against threats from hackers, and being mindful of which genomic tests they order (e.g., whole genome sequencing vs. a more limited test that still generates the necessary genomic information) and what information they document in the medical record. Finally, because HIPAA imposes a "minimum necessary" standard, which requires that covered entities such as clinicians limit unnecessary access to patient's health information, and because GINA bans the use of genetic information by health insurance companies and employers, psychiatrists arguably have both an ethical fiduciary obligation and a legal obligation to remove any genomic information when such entities request medical records.
Together, clinicians and patients must weigh the prospective clinical benefits of testing against the potential emotional and social harms, especially in those cases in which patients have no current symptoms of mental illness. Because testing asymptomatic individuals carries substantial risks and currently yields few benefits, clinicians should use caution in initiating genetic testing in asymptomatic individuals. If testing is pursued, and an asymptomatic individual is identified to be at increased risk, regular monitoring of symptoms, as well as psychoeducation and psychotherapy, currently seem more appropriate than pharmacological interventions.
Using Genomics to Substantiate Diagnosis
The vast majority of psychiatrists believe genomic testing will play a role in diagnosing autism, bipolar disorder, major depression, and schizophrenia. 21 Although no biomarkers are currently capable of definitively establishing a diagnosis of mental illness, genomic findings may be used to substantiate diagnoses. For example, copy-number variants such as 3q29 or 22q11.2 deletions could, in theory, be used to help substantiate a diagnosis of schizophrenia because of their association with the disorder. 5, 14, 24, 73, 74 As psychiatric genomics and neuroscience advance, it is reasonable to suggest that psychiatrists will increasingly use biomarkers as they formulate their diagnoses.
The increasing use of genetic testing for diagnostic purposes presents several challenges. Positive genetic-testing results could promote the inaccurate view that patients' behaviors are a product of their genes (genetic essentialism), leading to a sense of determinism that could prove to be dispiriting to patients and their providers. [75] [76] [77] By emphasizing biological factors, such findings could lead patients to engage less with psychotherapy, an outcome that would be particularly problematic in cases in which therapy is an effective treatment. To minimize some of these risks, it will be essential for clinicians to understand and carefully explain to patients the complex interplay between biological and psychosocial factors. Genetic testing for diagnostic purposes may also lead to increased stigmatization and discrimination. 37, 78, 79 Research suggests that when people know an individual's mental illness has a significant genetic component, this awareness decreases the perception that a patient is to blame for the symptoms, but potentially intensifies stigma by increasing the perceived seriousness and persistence of the disorder, the perception that the individual is dangerous, and the desire for social distance. 78, 79 Therefore, patients whose disorder is identified as having some genetic component are likely to be exposed to increased stigma unless widespread changes occur in understandings about genetic determinism. Clinicians and patients must weigh the social risks of genetic testing against its potential diagnostic value.
Because genetic testing results could potentially promote genetic determinism and stigma, generate emotional distress, and limit adherence to treatment (i.e., psychotherapy), psychiatrists face ethical challenges in deciding how to employ testing in their practices. First, psychiatrists need to decide whom to test. Ideally, professional organizations will generate guidelines and training to help psychiatrists make these determinations, as discussed above; in the clinic, however, psychiatrists will have to make final determinations about whether to offer genetic testing to specific individuals based on each patient's overall interests. Given that genetic findings may have potential genomic implications concerning relatives, another source of challenge regarding whom to test is that genomic findings may generate disputes or distress among family members. For example, parents may feel guilty because they believe they "passed on" pathogenic variants that led to symptoms; children may feel their parents are culpable for "passing on" those genes; and some relatives may not want to know the results of a patient's genetic testing because of the potential implications that it may have for them.
Psychiatrists also face ethical considerations when disclosing genetic results to patients. Patients themselves may experience self-stigma and share the view that a psychiatric disorder with genetic components is more serious and persistent. [78] [79] [80] [81] [82] [83] For this reason, invoking the principle of nonmaleficence, some psychiatrists may consider that in exceptional circumstances, particularly if the patient is currently debilitated, it may be in the patient's best interests not to immediately disclose the results of genetic testing to the patient. 84 In the vast majority of cases, however, psychiatrists will likely favor disclosing these findings out of a respect for patient autonomy 84 or because they believe that sharing such information could foster a stronger patient-physician relationship, or "therapeutic alliance." Given the potential for these competing interests to complicate clinical decision making, more research is needed on how patients respond to positive genetic findings, what may be the appropriate time to disclose such information, and how it should be disclosed.
A greater understanding of patient and clinician attitudes and of the impact of disclosing genetic findings may facilitate evidence-based recommendations on the use of diagnostic testing, which could reduce variation in clinical practices. Even with recommendations in place, however, to some extent psychiatrists will always need to make these decisions on a case-by-case basis. One way to mitigate this decisionmaking burden is to seek greater patient input as these issues arise. Psychiatrists should use the informed consent process as an occasion to discuss patients' attitudes about genetic testing, explore with them the implications of positive results, and offer them the choice of whether or not to be informed of the findings. Such a discussion would help clinicians and patients make decisions that are more in line with patients' values and interests, and may have the added benefit of fostering a stronger therapeutic alliance.
Using Genomics to Characterize a Psychiatric Condition
As noted above, no biomarkers are currently capable of establishing a diagnosis of mental illness. Several psychiatric conditions, however, are associated with known neuropathologies. 85 Using currently available genetic tests, psychiatrists may identify the neuropathological basis of certain of these psychiatric disorders. Clinicians may assess for LeschNyhan syndrome in a patient with intellectual disability and prominent self-injurious behaviors, 86 Huntington's disease in a patient with early-onset neurocognitive disorder, 87 or Fragile X syndrome in a patient with attention-deficit/ hyperactivity disorder and abnormal physical features. 88 Occasionally, genomic testing may call into question an already existing diagnosis. For example, testing may reveal that a patient previously diagnosed with schizophrenia actually likely suffers from Wilson's disease, a rare genetic condition that may cause psychotic symptoms and may be managed with copper-chelating agents and diet. 89 Psychiatrists face ethical and legal issues when deciding when to order tests for rare genetic conditions. Since failure to assess for these conditions may cause clinicians to miss treatable conditions, such as Wilson's disease, some clinicians may be inclined to order these tests on a routine basis. 5 While probably unusual, some may be reluctant to order a test that could reveal a diagnostic error, especially in cases where the psychiatrist is concerned that a misdiagnosis has led to improper medical treatment and provide the basis for a medical malpractice lawsuit. In any event, either of the available options-ordering tests or not ordering tests-presents the risk of performing a disservice to their patients. On the one hand, overuse of genetic testing may subject patients to unnecessary treatment (due to false positives) and may drive up the cost of health care, inconsistent with the ethical principles of nonmaleficence and justice. On the other hand, avoiding such testing may result in important information being withheld
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Harvard Review of Psychiatry www.harvardreviewofpsychiatry.org from patients, violating patients' autonomy, clinicians' fiduciary duty to look after patients' best interests, and the ethical principle of compassion. Psychiatrists should rely on their clinical judgment to avoid these extremes. Genetic testing may be useful for ruling out specific medical etiologies, particularly in patients with atypical presentations, positive family histories, or unexplained medical symptoms, but psychiatrists should avoid falling into the trap of practicing genetic "defensive medicine." Prognosis Currently, clinicians generate prognoses based on known risk factors. For example, it has long been known that patients with schizophrenia who have healthy premorbid social functioning and acute onset of illness fare better than those with more pronounced negative symptoms and gradual onset of illness. 90 With advances in genomics, researchers may soon be able to identify genetic biomarkers that predict worse outcomes or more severe phenotypes, just as oncologists now use biomarkers to predict disease outcomes and guide treatment choices.
As is the case with genomic testing to substantiate diagnoses, issues of stigma apply to the use of prognostic tests-and perhaps doubly so in the case of prognostic testing, given that it claims to predict not merely the presence, but the persistence, of disease. The use of testing to predict prognosis also has strong implications for treatment. Approximately 30% of patients with schizophrenia do not respond effectively to treatment, [91] [92] [93] [94] and ongoing studies may identify genomic correlates associated with treatment-resistant psychosis. 5, 24 Suppose, for example, that genetic testing reveals that a subset of patients with newly diagnosed schizophrenia is at risk for treatment-resistant schizophrenia. Such a finding may prompt psychiatrists to consider a trial of clozapine, a secondgeneration antipsychotic that is associated with better outcomes but is typically not used as a first-line agent because of the increased need for monitoring and higher risk of adverse effects. [95] [96] [97] In such cases, clinicians departing from the standard of care may be protected under what some refer to as the "reasonable innovation rule," which allows clinicians in the United States some degree of flexibility when they depart from the standard of care to conduct clinical innovations even if those innovations end up causing harm to patients. [98] [99] [100] [101] The purpose of this rule is to allow clinicians to innovate to address a patient's unique needs, but among other things, clinicians need to have carefully considered alternatives and any available literature or evidence to suggest that the innovative intervention might work. It is unclear how courts will view the use of genetic testing to determine prognosis or make determinations about other aspects of care. Guidelines from professional organizations would help provide guidance. But because genetic information can be applied in so many different ways in psychiatric practice, clinicians are encouraged to obtain more training in genomics and to determine the relevant local law for clinical-innovation cases. This information will help psychiatrists make informed decisions about how and when to use emerging genomic technologies.
Treatment
Although the potential clinical utility of pharmacogenetic tests in psychiatry is still being worked out, pharmacogenetics, in theory, has great potential to help guide treatment by predicting both treatment response and medication tolerability. For patients who are treatment naive, such findings may aid clinicians in choosing a suitable first-line medication. Pharmacogenetic findings pose unique challenges, however, in patients who have already been prescribed medication. For example, genetic testing may reveal that the medication a patient has been prescribed is more likely to be ineffective or to generate severe side effects than other treatments. For patients who are not in remission and for whom a change in treatment is indicated due to lack of response, such findings might suggest alternate treatment approaches. For patients relatively stable on their current regimen, however, such findings would pose a significant dilemma for clinicians. If, on the basis of pharmacogenomic testing, providers proposed medication changes that ultimately were unsuccessful, the result would be unnecessary inconvenience and suffering. Conversely, if, on the basis of the same testing, providers opted not to make a switch, only to find that the patients experienced severe side effects, disease recurrence, or worsening of symptoms that, for example, led to a suicide attempt, some might argue that the providers had been negligent. The clinician-patient relationship could also end up being compromised.
When using pharmacogenetic tests, it is critical to involve the patient (or the patient's legally authorized representative if the patient lacks decision-making capacity) in the decisionmaking process. This is particularly important with patients who are relatively stable in their current medication regimens. Given the probabilistic nature of genetic testing-even with the development of increasingly sophisticated tools to guide treatment selection-psychiatrists will continue to face difficult decisions in their day-to-day practices. By involving patients in the process, clinicians can mitigate potential harms, prescribe treatments that are more consistent with patients' values, and strengthen their therapeutic alliance.
CONCLUSION
In the sections above, we have sought to describe the nature of key challenges that genomics may present in psychiatric practice. Here, we synthesize and elaborate upon some of the recommendations made above to promote responsible decision making about genomic testing and about managing results. First, to the extent that the integration of genomics into clinical practice is hindered by a lack of genetics training, we propose that such training become a priority for medical schools, residency programs, and continuing medical education courses. eventually seek out programs that offer this training. A more immediately feasible route is to increase continuing medical education courses in psychiatric genomics. 103 Second, as psychiatric genomic knowledge develops and genomic testing increasingly enters psychiatric practice, there will undoubtedly be a period of uncertainty about what constitutes responsible use of these technologies. Professional organizations could help minimize this uncertainty, however, and promote responsible use of genomics by releasing well-informed and carefully crafted practice guidelines. Such guidelines would help to establish a standard of care and would go a long way in addressing clinician concerns regarding proper practice and legal liability related to the use of genomic findings.
Third, given the complexity of genomic information and the potential for genomic tests to reveal information related to both psychiatric and nonpsychiatric conditions, psychiatrists should continue to follow an integrated care model, in which psychiatrists work collaboratively with other clinicians. Already, the ACMG recommends that when clinical genomic sequencing is performed, laboratories should analyze the genes potentially associated with a patient's symptoms and also 59 genes that may reveal a risk for nonpsychiatric conditions (e.g., colon cancer, long QT syndrome) for which medical interventions exist. 41, 43 Therefore, if psychiatrists order genomic sequencing, they may have to manage findings that fall outside their areas of practice. In such cases-and, indeed, even when psychiatrists identify genomic findings with implications for mental health care-they should, if possible, involve colleagues such as medical geneticists and genetic counselors to ensure optimal clinical management. 5 Fourth, psychiatrists should place special emphasis on patient engagement, choice, and informed consent when ordering genomic testing. Given potential medical and social harms, it is imperative that clinicians take the time to educate their patients about the risks and benefits of genetic testing when they obtain informed consent. In addition to the standard elements of legally valid informed consent, this process should include, at a minimum, the following three elements: an explanation of the science underlying the test being ordered, including an acknowledgment of any of the test's limitations; a review of the test's clinical applications; and a discussion of the ethical and legal implications of testing (e.g., stigma, privacy concerns). Clinicians should take special care when obtaining informed consent in cases in which the use of genetic testing could dramatically alter the course of treatment, generate results that may be particularly stigmatizing, or foreseeably cause other harms.
The genomics era holds out much promise for psychiatry. Effective psychiatric practice, however-perhaps more than any other medical field-depends heavily on a deep understanding of the patient as an individual, and of disorders as having potentially complex etiologies and treatment trajectories that cannot be reduced solely to genetics. Diagnostic and treatment approaches that rely too heavily on genomics and other biomarkers have the potential to depersonalize psychiatric practice and erode the doctor-patient relationship. It is ultimately the responsibility of professional organizations to set proper guidelines and of individual psychiatrists to responsibly integrate novel technologies while maintaining their therapeutic alliances with patients and retaining the humanism that has long animated their profession.
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